TY - JOUR
T1 - Blood-based biomarkers for Alzheimer's disease
T2 - towards clinical implementation
AU - Teunissen, Charlotte E.
AU - Verberk, Inge M.W.
AU - Thijssen, Elisabeth H.
AU - Vermunt, Lisa
AU - Hansson, Oskar
AU - Zetterberg, Henrik
AU - van der Flier, Wiesje M.
AU - Mielke, Michelle M.
AU - del Campo, Marta
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/1
Y1 - 2022/1
N2 - For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent results have shown that they could become a reality. Convincing data generated with new high-sensitivity assays have emerged with remarkable consistency across different cohorts, but also independent of the precise analytical method used. Concentrations in blood of amyloid and phosphorylated tau proteins associate with the corresponding concentrations in CSF and with amyloid-PET or tau-PET scans. Moreover, other blood-based biomarkers of neurodegeneration, such as neurofilament light chain and glial fibrillary acidic protein, appear to provide information on disease progression and potential for monitoring treatment effects. Now the question emerges of when and how we can bring these biomarkers to clinical practice. This step would pave the way for blood-based biomarkers to support the diagnosis of, and development of treatments for, Alzheimer's disease and other dementias.
AB - For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but recent results have shown that they could become a reality. Convincing data generated with new high-sensitivity assays have emerged with remarkable consistency across different cohorts, but also independent of the precise analytical method used. Concentrations in blood of amyloid and phosphorylated tau proteins associate with the corresponding concentrations in CSF and with amyloid-PET or tau-PET scans. Moreover, other blood-based biomarkers of neurodegeneration, such as neurofilament light chain and glial fibrillary acidic protein, appear to provide information on disease progression and potential for monitoring treatment effects. Now the question emerges of when and how we can bring these biomarkers to clinical practice. This step would pave the way for blood-based biomarkers to support the diagnosis of, and development of treatments for, Alzheimer's disease and other dementias.
UR - http://www.scopus.com/inward/record.url?scp=85121457724&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121457724&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(21)00361-6
DO - 10.1016/S1474-4422(21)00361-6
M3 - Review article
C2 - 34838239
AN - SCOPUS:85121457724
SN - 1474-4422
VL - 21
SP - 66
EP - 77
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 1
ER -